Approach to Mucormycosis Caused by Rhizopus
Immediate First-Line Treatment
- The American College of Physicians and Infectious Diseases Society of America recommend starting liposomal amphotericin B at a minimum of 5 mg/kg/day immediately upon diagnosis, with a strong recommendation for surgical debridement and reversal of underlying predisposing conditions 1, 2, 3, 4
- For patients with central nervous system involvement, the guideline recommends escalating the dose to 10 mg/kg/day 4
- The Infectious Diseases Society of America advises against using amphotericin B deoxycholate due to severe adverse effects, particularly nephrotoxicity 1, 2, 3
Diagnostic Confirmation
- The European Society of Clinical Microbiology and Infectious Diseases recommends obtaining direct microscopy, histopathology, and culture for diagnostic confirmation, with a strong recommendation for identifying the pathogen to species level using molecular methods 1, 3
- Imaging is strongly recommended to determine the extent of disease, with a moderate strength recommendation for looking for the reverse halo sign on CT to differentiate mucormycosis from aspergillosis in hematological malignancy and stem cell transplant recipients 1, 3
Salvage and Second-Line Treatment
- The Infectious Diseases Society of America recommends posaconazole 400 mg twice daily as salvage therapy, with a strong recommendation for combination therapy options including lipid amphotericin B plus caspofungin or posaconazole 1, 2, 3, 5, 4
Treatment Duration and Monitoring
- The American College of Physicians recommends continuing treatment until complete response on imaging and permanent reversal of predisposing factors, with a strong recommendation for considering maintenance therapy with posaconazole after initial treatment 1, 2, 3, 4